Heptares to Present at Upcoming Scientific and Biotech Industry Conferences
WELWYN GARDEN CITY, England and BOSTON, April 16, 2013 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR drug discovery company, notes that it will be presenting at the following scientific conferences and biotech industry events over the coming weeks.
8th Annual Drug Discovery Chemistry (San Diego, CA, USA, April 16-18)
Dr Rob Cooke, Heptares' Head of Biomolecular Structure, will give a presentation entitled "Utilizing Structural Insights in GPCR Drug Discovery" as part of the GPCR-Based Drug Design stream (2:40pm, 17 April). Dr Cooke will also be hosting an evening workshop on "Practical Aspects of Structure-based Drug Discovery with GPCRs" at the meeting.
2013 BIO International Convention (22-25 April, Chicago, IL, USA)
Mr Dan Grau (President) will present an overview of the Company during the BioBusiness Forum, which takes place from 8:00am-11:00am on 24 April. Dr Barry Kenny (Chief Business Officer) and Dr Cath Hutchings (Antibody Discovery & Strategic Partnering) will also be present at the event.
4th GPCR Colloquium at The American Society for Pharmacology and Experimental Therapeutics (ASPET) meeting (Boston, MA, USA, 24-25 April)
Dr Fiona Marshall, Heptares' Chief Scientific Officer, will present a talk entitled "X-ray Structures for the Predictive Generation of GPCR Drugs" (2:15pm, 25 April).
6th Annual Diabetes Summit (29-30 April, Boston, MA, USA)
Mr Dan Grau, Heptares' President, will participate in two panel discussions as part of the Diabetes Partnering and Deal Making stream: the panels are entitled "Innovative Partnering & Licensing Strategies" (3:30pm, 29 April) and "Type 2 Diabetes Innovation" (10:20am, 30 April).
Gordon Research Conference on Molecular Pharmacology (28 April-3 May, Lucca, Italy)
Dr Kaspar Hollenstein, Senior Scientist at Heptares, will give a presentation entitled "Using Thermostabilized Receptors to Obtain Crystal Structures of Family A and Family B G protein-coupled Peptide Receptors" (7:00pm, 1 May).
For a full list of events at which Heptares will be present, please visit http://www.heptares.com
About Heptares Therapeutics
Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Shire, Cubist, Takeda, MorphoSys, AstraZeneca and MedImmune, and we are backed by MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com.
SOURCE Heptares Therapeutics